Use of a reverse-micellar system for delivering chelators of radionuclides and metals

Abstract

The present invention relates to reverse-micellar systems comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water, for use in chelation and/or sequestering of a radionuclide and/or a metal in a patient. The invention also relates to the reverse-micellar systems and to pharmaceutical compositions comprising said reverse-micellar systems.

1 . A method for treating at least one disease linked to the accumulation, overload, or accumulation and overload of at least one radionuclide or metal comprising administering a reverse-micellar system comprising at least an active agent, an acylglycerol, a sterol, lecithin, ethanol and water to a patient in need thereof, wherein the active agent chelates at least one metal, chelates at least one radionuclide, sequesters at least one metal, or sequesters at least one radionuclide. 
     
     
         2 . The method according to  claim 1 , wherein the active agent is DTPA, bisphosphonates, Prussian blue, EDTA, Trientine, D-penicillamine, Deferoxamine, BAL, DMSA, DMPS, Phytic acid, Hydroxypyridonates (HOPO), mercaptoacetyltriglycine (MAG3), chelating peptides, derivatives thereof or combinations thereof. 
     
     
         3 . (canceled) 
     
     
         4 . The method according to  claim 1 , wherein the disease is Wilson's disease, haemochromatosis or a pathology or symptom due to a metal accumulation from an external origin. 
     
     
         5 . The method according to  claim 1 , wherein the reverse-micellar system is administered transmucosally. 
     
     
         6 . (canceled) 
     
     
         7 . The method according to  claim 1 , wherein the sterol is sitosterol. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein the active agent is pentetate calcium trisodium (CaNa 3  DTPA). 
     
     
         17 . The method of  claim 1 , wherein the active agent has a concentration of 1-124.4 mg/g. 
     
     
         18 . The method according to  claim 5 , comprising administering said reverse-micellar system through the buccal mucosal tissue.